Shots:
Minjuvi (tafasitamab) + lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province under the early access program in Boao Lecheng International Medical Tourism Pilot Zonea whereas, the first prescription of tafasitamab + lenalidomide was filled at the Ruijin Hainan Hospital in China for an eligible DLBCL patient
Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAB and it is not approved by the NMPA for any indication except this early access program
Earlier, this combination received conditional approval by the US FDA & the EMA for the treatment of r/r DLBCL patients who are not eligible for autologous stem cell transplant
Ref: Bussinesswire | Image: InnoCare
